Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Anthera Pharmaceuticals Inc.
  • AstraZeneca Plc
  • BIND Therapeutics Inc.
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Celldex Therapeutics Inc.
  • Cellular Biomedicine Group Inc.
  • Cempra Inc.
  • Cerus Corp.
  • CytoSorbents Corp.
  • Five Prime Therapeutics
  • Incyte Corp.
  • Isis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • NeoStem Inc.
  • Novavax Inc.
  • Omeros Corp.
  • OncoGenex Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmacyclics Inc.
  • Roche Holding AG
  • Sangamo BioSciences Inc.
  • Verastem Inc.
  • Ziopharm Oncology Inc.

John McCamant

Medical Technology Stock Letter

Image: John McCamant

John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.

The Medical Technology Stock Letter has earned the #1 ranking from Hulbert's Financial Digest. >Read More




Recent Interviews

Fire Up the Immune System to Fight Cancers and Boost Portfolios: John McCamant (5/12/15) An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.

Will Biotech Fire on All Cylinders in 2015? (12/30/14) Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before rebounding, essentially following the upward trend that most experts forecast. What is in store for 2015? The Life Sciences Report turned to newsletter writer John McCamant and WBB Securities' Steve Brozak for insight.

Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound (11/6/14) When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance of Streetwise Reports' Biotechnology Watchlist to date reflects this trend: The portfolio lingered in negative territory after the late-winter punch, and hovers near breakeven as of Nov. 3. To get a handle on the drivers of small-cap stock price volatility, The Life Sciences Report turned to a pair of the analysts who selected companies for the 2014 Watchlist, John McCamant of the Medical Technology Stock Letter and George Zavoico of MLV & Co. In this recap, the two experts offer updates on the companies they selected for the portfolio.

Recent Quotes

"CBMG is a recently transformed company." (5/12/15) Cellular Biomedicine Group Inc. - The Life Sciences Report with John McCamant More >

"We continue to believe that OGXI is undervalued." (12/21/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"The potential of CYCC's phase 3 trial with AML gives the Street more confidence." (10/25/12) Cyclacel Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >

"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger." (10/4/12) OncoGenex Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >

"We continue to believe that OGXI is undervalued." (7/20/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"Data from OGXI's phase 2 trial for OGX-427 is encouraging." (6/8/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"We are pleased OGXI is flexible in its OGX-011 development plans." (3/16/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"OGXI could be a home-run stock." (2/23/12) OncoGenex Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >



Due to permission requirements, not all quotes are shown.